Comparison of insulin degludec with insulin detemir in type 1 diabetes: a 1‐year treat‐to‐target trial
This study confirmed the long‐term safety and tolerability profile of IDeg in participants with T1DM. IDeg provided a lower risk of nocturnal confirmed hypoglycaemia than IDet. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - September 7, 2015 Category: Endocrinology Authors: Melanie Davies, Takashi Sasaki, Jorge Luiz Gross, Ganapathi Bantwal, Yuri Ono, Tomoyuki Nishida, Damon Tojjar, Hiroaki Seino Tags: RESEARCH LETTER Source Type: research
Body Composition and Epicardial Fat in Type 2 Diabetes Patients Following Insulin Detemir Versus Insulin Glargine Initiation
In conclusion, detemir resulted in less fat mass gain, a trend for a more pronounced epicardial fat thickness reduction when compared with glargine.[...]© Georg Thieme Verlag KG Stuttgart · New YorkArticle in Thieme eJournals:Table of contents | Abstract | Full text (Source: Hormone and Metabolic Research)
Source: Hormone and Metabolic Research - September 4, 2015 Category: Endocrinology Authors: Elisha, B.Azar, M.Taleb, N.Bernard, S.Iacobellis, G.Rabasa-Lhoret, R. Tags: Endocrine Care Source Type: research
Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients
ConclusionsIDeg has a flat, consistent and ultra‐long glucose‐lowering effect that is evenly distributed across a 24‐h interval and an ultra‐long duration of action in Japanese patients with type 1 diabetes. These data support once‐daily dosing of IDeg in all patients. Overall, the pharmacodynamic and pharmacokinetic end‐points and safety observations are consistent with those previously reported in Caucasian patients.
This study aimed to evaluate the pharmacokinetic and pharmacodynamic properties of insulin degludec (IDeg) in Japanese patients with type 1 diabetes mellitus (T1DM). Patients were randomized in...
Source: Journal of Diabetes Investigation - August 27, 2015 Category: Endocrinology Authors: Ippei Ikushima, Kohei Kaku, Koichi Hirao, Lars Bardtrum, Hanne Haahr Tags: Clinical Trial Source Type: research
Effect of Subcutaneous Insulin Detemir on Glucose Flux, Lipolysis and Electroencephalography in Type 1 Diabetes.
Abstract
To investigate the effects of subcutaneous detemir on glucose flux, lipid metabolism and brain function, twelve people with type 1 diabetes received in random order 0.5Units/kgBW detemir or NPH insulin. Glucose concentration was clamped at 5mmol/L then increased to 10mmol/L. Glucose production rate (glucose Ra), glucose uptake (glucose Rd) and glycerol production (glycerol Ra) were measured with a constant iv infusion of [6,6(2) H2 ]glucose and [(2) H5 ]glycerol. Electroencephalography direct (DC) and alternating (AC) current potentials were measured. While detemir induced comparable effects on gl...
Source: Diabetes Metab - August 14, 2015 Category: Endocrinology Authors: Herring R, Knight R, Shojaee-Moradie F, Johnsen S, Umpleby AM, Jackson N, Jones R, Dijk DJ, Russell-Jones DL Tags: Diabetes Obes Metab Source Type: research
Bioavailability of insulin detemir and human insulin at the level of peripheral interstitial fluid in humans assessed by open flow microperfusion.
CONCLUSIONS: OFM proved useful for target tissue measurements of human insulin and the analogue insulin detemir. Our tissue data confirm a highly effective retention of insulin detemir in the vascular compartment. The higher insulin detemir relative to human insulin tissue concentrations at comparable pharmacodynamics, however, indicate that the lower potency of insulin detemir in humans is due to a reduced effect in peripheral insulin sensitive tissues and is in line with the reduced in-vitro receptor affinity.
PMID: 26260082 [PubMed - as supplied by publisher] (Source: Diabetes Metab)
Source: Diabetes Metab - August 11, 2015 Category: Endocrinology Authors: Bodenlenz M, Ellmerer M, Schaupp L, Jacobsen LV, Plank J, Brunner GA, Wutte A, Aigner B, Mautner SI, Pieber TR Tags: Diabetes Obes Metab Source Type: research
Bioavailability of insulin detemir and human insulin at the level of peripheral interstitial fluid in humans assessed by open flow microperfusion
ConclusionsOFM proved useful for target tissue measurements of human insulin and the analogue insulin detemir. Our tissue data confirm a highly effective retention of insulin detemir in the vascular compartment. The higher insulin detemir relative to human insulin tissue concentrations at comparable pharmacodynamics, however, indicate that the lower potency of insulin detemir in humans is due to a reduced effect in peripheral insulin sensitive tissues and is in line with the reduced in‐vitro receptor affinity. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - August 11, 2015 Category: Endocrinology Authors: M. Bodenlenz, M. Ellmerer, L. Schaupp, L. V. Jacobsen, J. Plank, G. A. Brunner, A. Wutte, B. Aigner, S. I. Mautner, T. R. Pieber Tags: ORIGINAL ARTICLE Source Type: research
Weight‐sparing effect of insulin detemir: a consequence of central nervous system‐mediated reduced energy intake?
Insulin therapy is often associated with adverse weight gain. This is attributable, at least in part, to changes in energy balance and insulin's anabolic effects. Adverse weight gain increases the risk of poor macrovascular outcomes in people with diabetes and should therefore be mitigated if possible. Clinical studies have shown that insulin detemir, a basal insulin analogue, exerts a unique weight‐sparing effect compared with other basal insulins. To understand this property, several hypotheses have been proposed. These explore the interplay of efferent and afferent signals between the muscles, brain, liver, renal and ...
Source: Diabetes, Obesity and Metabolism - August 11, 2015 Category: Endocrinology Authors: D. Russell‐Jones, T. Danne, K. Hermansen, K. Niswender, K. Robertson, N. Thalange, J. R. Vasselli, B. Yildiz, H. U. Häring Tags: REVIEW ARTICLE Source Type: research
Effect of Subcutaneous Insulin Detemir on Glucose Flux, Lipolysis and Electroencephalography in Type 1 Diabetes
Abstract
To investigate the effects of subcutaneous detemir on glucose flux, lipid metabolism and brain function, twelve people with type 1 diabetes received in random order 0.5Units/kgBW detemir or NPH insulin. Glucose concentration was clamped at 5mmol/L then increased to 10mmol/L. Glucose production rate (glucose Ra), glucose uptake (glucose Rd) and glycerol production (glycerol Ra) were measured with a constant iv infusion of [6,62H2]glucose and [2H5]glycerol. Electroencephalography direct (DC) and alternating (AC) current potentials were measured. While detemir induced comparable effects on glucose Ra, glucose Rd and ...
Source: Diabetes, Obesity and Metabolism - August 1, 2015 Category: Endocrinology Authors: Roselle Herring, Richard Knight, Fariba Shojaee‐Moradie, Sigurd Johnsen, A.Margot Umpleby, Nicola Jackson, Richard Jones, Derk‐Jan Dijk, David L. Russell‐Jones Tags: RESEARCH LETTER Source Type: research
Effect of a new insulin treatment regimen on glycaemic control and quality of life of Muslim patients with type 2 diabetes mellitus during Ramadan fast – an open label, controlled, multicentre, cluster randomised study
Summary
We performed a non‐inferiority trial comparing insulin detemir (Levemir) and biphasic insulin (NovoMix70) to standard care during Ramadan fast in insulin treated type 2 diabetes mellitus (T2DM) patients. This was an open label, controlled, multicentre, cluster randomised non‐inferiority study. Insulin treated T2DM patients from 12 randomly selected primary clinics received Levemir and NovoMix 70 (intervention, n = 127) or standard care according to the American Diabetes Association recommendations (control, n = 118). Insulin dose (intervention) was 60% of the usual, of this 40% was dosed as Levemir at sunri...
Source: International Journal of Clinical Practice - July 31, 2015 Category: Internal Medicine Authors: N. Shehadeh, Y. Maor, Tags: Original Paper Source Type: research
Severe hypoglycaemia in adults with insulin‐treated diabetes: impact on healthcare resources
ConclusionThis analysis suggests that severe hypoglycaemia events often result in emergency/ambulance calls and hospital treatment, incurring a substantial health economic burden, and were associated with all insulin regimens. (Source: Diabetic Medicine)
Source: Diabetic Medicine - July 16, 2015 Category: Endocrinology Authors: S. R. Heller, B. M. Frier, M. L. Hersløv, J. Gundgaard, S. C. L. Gough Tags: Research: Complications Source Type: research
Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese subjects with type 1 diabetes mellitus reflect similarities with Caucasian subjects
ConclusionsIDeg has a flat, consistent and ultra‐long glucose‐lowering effect that is evenly distributed across a 24‐hour interval and an ultra‐long duration of action in Japanese subjects with type 1 diabetes. These data support once‐daily dosing of IDeg in all patients. Overall, the pharmacodynamic and pharmacokinetic endpoints and safety observations are consistent with those previously reported in Caucasian subjects.This article is protected by copyright. All rights reserved. (Source: Journal of Diabetes Investigation)
Source: Journal of Diabetes Investigation - July 14, 2015 Category: Endocrinology Authors: Ippei Ikushima, Kohei Kaku, Koichi Hirao, Lars Bardtrum, Hanne Haahr Tags: Clinical Trial Source Type: research
Clinical and financial outcomes of switching insulin glargine to insulin detemir in a veteran population with type 2 diabetes
Conclusion
The increase in A1c and TDD following conversion from insulin glargine to insulin detemir suggests that glargine requires a smaller amount of units to reach the same glycemic-lowering ability compared to detemir. Despite the observed insulin cost savings associated with detemir, future studies should also determine overall costs (including indirect) and benefits associated with switching from glargine to detemir among Veteran with Type 2 diabetes. (Source: Journal of Diabetes and Metabolic Disorders)
Source: Journal of Diabetes and Metabolic Disorders - June 26, 2015 Category: Endocrinology Source Type: research
Insulin Detemir Is Transported From Blood to Cerebrospinal Fluid and Has Prolonged Central Anorectic Action Relative to NPH Insulin
Insulin detemir (DET) reduces glycemia comparably to other long-acting insulin formulations but causes less weight gain. Insulin signaling in the brain is catabolic, reducing food intake. We hypothesized that DET reduces weight gain, relative to other insulins, owing to increased transport into the central nervous system and/or increased catabolic action within the brain. Transport of DET and NPH insulin into the cerebrospinal fluid (CSF) was compared over several hours and after the administration of different doses peripherally in rats. DET and NPH had comparable saturable, receptor-mediated transport into the CSF. CSF i...
Source: Diabetes - June 23, 2015 Category: Endocrinology Authors: Begg, D. P.; May, A. A.; Mul, J. D.; Liu, M.; D'Alessio, D. A.; Seeley, R. J.; Woods, S. C. Tags: Obesity Studies Source Type: research
Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus
This article updates an earlier review of exenatide ER in the management of type 2 diabetes, focusing on recently published data. In randomized, controlled trials, adjunctive exenatide ER 2 mg once weekly for 24–30 weeks significantly improved glycaemic control and reduced bodyweight in patients with inadequately controlled type 2 diabetes despite diet plus exercise and/or oral antihyperglycaemic drugs (OADs). These beneficial effects of exenatide ER were maintained after up to 6 years of treatment. In patients receiving one or more OADs, addition of exenatide ER provided better glycaemic control than an immediate-rel...
Source: Drugs - June 13, 2015 Category: Drugs & Pharmacology Source Type: research
Randomized Controlled Trial of Insulin Detemir versus NPH for the Treatment of Pregnant Women with Diabetes
To determine if insulin detemir (IDet) is non-inferior to insulin NPH for the treatment of gestational diabetes (GDM) and type 2 diabetes in pregnancy (T2DM). (Source: American Journal of Obstetrics and Gynecology)
Source: American Journal of Obstetrics and Gynecology - June 9, 2015 Category: OBGYN Authors: Kimberly M. Herrera, Barak M. Rosenn, Janelle Foroutan, Brianne E. Bimson, Zainab AL. Ibraheemi, Erin L. Moshier, Lois E. Brustman Source Type: research
